Ann: 2024 EGM Letter to Shareholders and Proxy, page-3

Recent interview from CEO very interesting:

“So, we have initiated those safety studies, so we'll be reporting readouts from those studies. We're also running a study with the Walter Reed Army Institute of Research, and this is a division of the US Department of Defense, and they were set up specifically to research traumatic brain injury, and they've been big supporters of the program and they have a model that we want to test the drug in, and it's a model of penetrating ballistic brain injury. So, it kind of reflects the sort of injuries that soldiers receive on the battlefield. So, that study's about to get underway and we'll be reporting on that and we'll be giving regular updates to the market as we progress forward to the clinic.”